Patents by Inventor Michael Dewitt Culler

Michael Dewitt Culler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200360483
    Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.
    Type: Application
    Filed: February 3, 2020
    Publication date: November 19, 2020
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, John E. Taylor, Rakesh Datta, Michael DeWitt Culler
  • Publication number: 20190111105
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Application
    Filed: December 19, 2018
    Publication date: April 18, 2019
    Applicants: Ipsen Pharma S.A.S., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Heather A. HALEM, Michael DeWitt CULLER, Andrew A. BUTLER
  • Publication number: 20180303899
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Application
    Filed: November 2, 2017
    Publication date: October 25, 2018
    Applicants: Ipsen Pharma S.A.S., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Heather A. HALEM, Michael DeWitt CULLER, Andrew A. BUTLER
  • Patent number: 9827286
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: November 28, 2017
    Assignees: Ipsen Pharma S.A.S., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Heather A. Halem, Michael DeWitt Culler, Andrew A. Butler
  • Publication number: 20170304403
    Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 26, 2017
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, John E. TAYLOR, Rakesh DATTA, Michael DeWitt CULLER
  • Publication number: 20160354429
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Application
    Filed: August 22, 2016
    Publication date: December 8, 2016
    Applicants: Ipsen Pharma S.A.S., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Heather A. HALEM, Michael DeWitt CULLER, Andrew A. BUTLER
  • Patent number: 9439943
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: September 13, 2016
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Heather A. Halem, Michael DeWitt Culler, Andrew A. Butler
  • Publication number: 20160206700
    Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.
    Type: Application
    Filed: January 18, 2016
    Publication date: July 21, 2016
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, John E. Taylor, Rakesh Datta, Michael DeWitt Culler
  • Publication number: 20150366934
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Application
    Filed: September 3, 2015
    Publication date: December 24, 2015
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Heather A. Halem, Michael DeWitt Culler, Andrew A. Butler
  • Patent number: 9155777
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: October 13, 2015
    Assignees: Ipsen Pharma S.A.S., Louisiana State University
    Inventors: Heather A. Halem, Michael Dewitt Culler, Andrew A. Butler
  • Publication number: 20150111823
    Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.
    Type: Application
    Filed: October 27, 2014
    Publication date: April 23, 2015
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Zheng Xin Dong, John E Taylor, Rakesh Datta, Michael DeWitt Culler
  • Patent number: 8871706
    Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogous of native hGhrelin.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: October 28, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Michael DeWitt Culler, Rakesh Datta, John E. Taylor
  • Patent number: 8822442
    Abstract: The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions.
    Type: Grant
    Filed: October 28, 2005
    Date of Patent: September 2, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Michael Dewitt Culler, Yeelena Shen
  • Patent number: 8741835
    Abstract: A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, H-Inp-D-Bal-D-Trp-Phe-Apc-NH2 (SEQ ID NO:73) or other suitable ghrelin agonist, to counteract the catabolic effects of dexamethasone and other natural glucocorticoids.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: June 3, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Giovanni Tulipano, Andrea Giustina, Zheng Xin Dong, Michael DeWitt Culler
  • Publication number: 20130331324
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of dyslipidemia and associated complications such as alcoholic and non-alcoholic fatty liver disease.
    Type: Application
    Filed: August 21, 2013
    Publication date: December 12, 2013
    Applicant: Ipsen Pharma, S. A. S.
    Inventors: Heather A. HALEM, Michael DeWitt CULLER
  • Patent number: 8258094
    Abstract: The invention comprises peptidyl analogs according to formulae (I) or (II) as depicted below: (R2R3)-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13- A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25- A-26-A27-A28-R1 wherein the definitions of A1 to A28 and R1 to R3 are provided for in the specification for each of formulae (I) and (II), pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising an effective amount of a compound of formula (I), that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: September 4, 2012
    Assignee: IPSEN Pharma S.A.S.
    Inventors: Zheng Xin Dong, Michael DeWitt Culler, Yeelana Shen, Jeanne Mary Comstock
  • Patent number: 8236762
    Abstract: The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.
    Type: Grant
    Filed: October 17, 2007
    Date of Patent: August 7, 2012
    Assignee: IPSEN Pharma S.A.S.
    Inventors: Zheng Xin Dong, Yeelana Shen, Michael DeWitt Culler, Christophe Alain Thurieau, Jundong Zhang, Sun Hyuk Kim
  • Publication number: 20120135923
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of dyslipidemia and associated complications such as alcoholic and non-alcoholic fatty liver disease.
    Type: Application
    Filed: July 30, 2010
    Publication date: May 31, 2012
    Applicant: IPSEN PHARMA, S.A.S.
    Inventors: Heather A. Halem, Michael DeWitt Culler
  • Publication number: 20120129767
    Abstract: A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib2, Glu3(NH-hexyl)]hGhrelin(1-28)-NH2 (SEQ ID NO:2) or other suitable ghrelin agonist, to counteract the catabolic effects of said dexamethasone and other natural glucocorticoids.
    Type: Application
    Filed: November 2, 2011
    Publication date: May 24, 2012
    Inventors: Giovanni Tulipano, Andrea Giustina, Zheng Xin Dong, Michael DeWitt Culler
  • Patent number: 8076281
    Abstract: A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib2, Glu3(NH-hexyl)]hGhrelin(1-28)-NH2 (SEQ ID NO:2) or other suitable ghrelin agonist, to counteract the catabolic effects of said dexamethasone and other natural glucocorticoids.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: December 13, 2011
    Assignee: IPSEN Pharma, S.A.S.
    Inventors: Giovanni Tulipano, Andrea Giustina, Zheng Xin Dong, Michael DeWitt Culler